A cancer treatment. In August 2026, Merck and Moderna announced that the Phase III INTerpath-001 trial of intismeran autogene, also known as V940 or mRNA-4157, in combination with pembrolizumab (Keytruda) met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival.
The trial enrolled 1,137 patients with high-risk stage IIB–IV cutaneous melanoma whose tumors had been completely removed by surgery. Patients received either intismeran plus pembrolizumab or pembrolizumab alone as adjuvant therapy intended to eliminate residual cancer cells and reduce the risk of relapse. According to the companies, the combination produced statistically significant and clinically meaningful improvements over pembrolizumab alone, with no new safety signals identified. Overall-survival follow-up is continuing, and detailed Phase III results have not yet been fully presented.
This distinction is important: the frequently reported 49% reduction in the risk of recurrence or death and 59% reduction in the risk of distant metastasis or death came from the earlier Phase IIb KEYNOTE-942 study—not from the newly announced Phase III analysis. Nevertheless, the Phase III result represents a major milestone: it is the first positive late-stage study of an individualized neoantigen therapy and an mRNA-based cancer treatment.
Why melanoma and other solid tumors remain difficult to treat
Surgery can cure some solid tumors when they are detected early and remain localized. Once cancer cells invade surrounding tissues or spread to distant organs, however, treatment becomes substantially more difficult. Prognosis varies widely according to cancer type, molecular characteristics, stage, and response to therapy, but metastatic disease generally remains the greatest therapeutic challenge.
Several new treatment platforms—including immune-checkpoint inhibitors, CAR-T cells, bispecific antibodies, and antibody–drug conjugates—have transformed parts of oncology. CAR-T therapies have been particularly successful in certain leukemias, lymphomas, and multiple myeloma, where malignant cells are readily accessible and often express well-defined targets. Solid tumors present additional obstacles: greater genetic diversity, limited immune-cell penetration, heterogeneous antigen expression, and a tumor microenvironment that can suppress immune activity.
Melanoma is a compelling target for immunotherapy because it often carries a high number of mutations. Some of these mutations generate neoantigens—abnormal peptide sequences that can be recognized by T cells as foreign. The challenge is that each patient’s tumor may display a different set of neoantigens, making a personalized strategy especially attractive.
Preventive and therapeutic cancer vaccines
Cancer vaccines fall into two broad categories.
Preventive vaccines protect against infections that can later cause cancer. Vaccination against human papillomavirus (HPV), for example, can prevent infections responsible for most cervical cancers and many anal, penile, vulvar, vaginal, and oropharyngeal cancers. Hepatitis B vaccination reduces the risk of chronic HBV infection, cirrhosis, and hepatocellular carcinoma. These vaccines work before cancer develops.
Therapeutic cancer vaccines are different. They are administered to people who already have cancer, or whose tumors have been removed but who remain at risk of recurrence. Their purpose is to teach or strengthen the immune system to recognize and destroy malignant cells. They may be used alone, but many appear more effective when combined with checkpoint inhibitors or other treatments that remove the brakes on antitumor immunity.
How a personalized mRNA cancer vaccine is made
Intismeran is designed specifically for each patient. Tumor tissue and a normal sample are analyzed to identify tumor-specific mutations. Computational algorithms then predict which mutations are most likely to generate neoantigens that can be processed by cells, displayed by major histocompatibility complex molecules, and recognized by T cells.
Up to 34 selected neoantigens are encoded in a customized mRNA construct. After administration, the mRNA instructs cells to produce the corresponding antigen fragments. These fragments are presented to the immune system, activating tumor-specific CD8+ cytotoxic T cells and CD4+ helper T cells. The goal is to create a broad immune response capable of finding and eliminating microscopic residual melanoma cells.
Pembrolizumab complements this approach. It blocks PD-1, an inhibitory receptor that tumors can exploit to weaken T-cell activity. In simple terms, the vaccine helps identify the targets, while pembrolizumab helps the activated immune cells sustain their attack.
Tumor-associated antigens and tumor-specific antigens
The selection of the right antigen is one of the central challenges in cancer-vaccine development.
Tumor-associated antigens (TAAs), such as carcinoembryonic antigen, prostate-specific antigen, alpha-fetoprotein, CA-125, and MUC1, may be overexpressed by cancer cells but can also occur in normal tissues. Because the immune system is normally trained to tolerate self-proteins, strong T cells against these antigens may be absent or suppressed. Targeting TAAs can therefore produce limited immune responses and, in some cases, carries a risk of damaging healthy tissue.
Tumor-specific antigens (TSAs) are restricted to cancer cells. Neoantigens created by somatic mutations are an important class of TSAs because they are absent from healthy cells and have not been subject to the same degree of immune tolerance. This gives them the potential to generate highly specific antitumor responses with less on-target injury to normal tissues.
Not every mutation produces a useful neoantigen, however. Candidate peptides must be generated inside the cell, transported and presented efficiently, bind the patient’s particular HLA molecules, and activate functional T cells. Whole-exome sequencing, RNA sequencing, mass spectrometry, and increasingly sophisticated bioinformatics are therefore used together to identify the most promising targets. AI can assist with ranking candidates, but experimental and clinical validation remain essential.
Researchers are also identifying cancer-specific antigens that arise from abnormal gene expression, altered RNA processing, and genomic regions once considered non-coding. If some of these antigens are shared across patients and tumor types, they could support more affordable “off-the-shelf” vaccines that do not require individual manufacturing.
Therapeutic cancer vaccines already in clinical use
The concept of stimulating immunity against an existing cancer is not new. Bacillus Calmette–Guérin (BCG), a weakened bacterium administered directly into the bladder, has long been used to treat high-risk non-muscle-invasive bladder cancer.
Sipuleucel-T (Provenge), approved by the FDA in 2010 for certain patients with metastatic castration-resistant prostate cancer, is an individualized cellular immunotherapy. A patient’s immune cells are collected, exposed to a prostate-cancer-associated antigen linked to an immune-stimulating factor, and then infused back into the patient.
Talimogene laherparepvec (T-VEC; Imlygic) is a genetically modified herpes simplex virus approved for certain melanoma lesions that cannot be surgically removed. It is injected into tumors, where it promotes cancer-cell destruction and stimulates an immune response. It is more precisely described as an oncolytic viral immunotherapy, although it is often discussed within the broader cancer-vaccine field.
These treatments demonstrate that therapeutic vaccination can work, but they also illustrate the diversity of the field. Current platforms include peptides, proteins, DNA, mRNA, viral vectors, virus-like particles, whole tumor cells, dendritic cells, and oncolytic viruses.
A rapidly expanding clinical pipeline
Personalized neoantigen vaccines are now being evaluated in melanoma, non-small cell lung cancer, pancreatic cancer, colorectal cancer, kidney cancer, bladder cancer, and other solid tumors. Roche and BioNTech, for example, are developing autogene cevumeran, another individualized mRNA neoantigen therapy, in postoperative settings including pancreatic and colorectal cancer.
Other platforms are also advancing. Tedopi is an off-the-shelf combination of tumor-associated peptides developed for HLA-A2-positive patients. TG4050 uses patient-specific neoantigens delivered through a viral vector and is being investigated in HPV-negative head and neck cancer. Personalized dendritic-cell vaccines, including neoantigen-loaded monocyte-derived dendritic cells, are also being explored, frequently in combination with PD-1 inhibitors.
Early clinical responses are encouraging, but small, uncontrolled studies must be interpreted cautiously. A durable response in one patient—or an apparent difference between small treatment groups—can generate a valuable hypothesis, but it cannot establish efficacy. Randomized trials with adequate follow-up are needed to determine whether a vaccine improves recurrence-free survival, overall survival, or quality of life.
What the Phase III milestone means
The INTerpath-001 announcement does not mean that a universal cancer vaccine has arrived, nor does it yet establish an overall-survival benefit. It does, however, provide the strongest evidence so far that a vaccine individually designed from a patient’s tumor can improve clinically meaningful outcomes when added to established immunotherapy.
Important questions remain. How durable will the benefit be? Which patients are most likely to respond? Can manufacturing be accelerated and made affordable? Will tumors escape by losing targeted antigens? Can similar results be achieved in cancers with fewer mutations or more immunosuppressive environments?
Despite these challenges, the direction is clear. Cancer vaccination is moving from a long-standing scientific ambition toward a practical form of precision immunotherapy. Personalized vaccines may help eliminate residual disease after surgery, while shared-antigen vaccines may eventually extend this strategy to larger patient populations. The positive Phase III melanoma result is therefore more than a success for one product: it is evidence that mRNA technology can be used not only to prevent infectious disease, but also to train the immune system against the unique molecular signature of an existing cancer.
Image credit: Portions of the figure in this article were generated using ChatGPT (OpenAI) or Google Gemini.
Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.
About Marin Biologic Laboratories
Our Recent Publication/Meeting Presentation on Gene Therapy
1. Development of VNX-101, an Adeno-Associated Virus with Less Immunogenicity and Efficient Long-Term Expression of a CD19 T-Cell Engager. Molecular Therapy Methods & Clinical Development, published online July 24, 2025.
3. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. Journal of Immunological Methods. 2025. 545-114004.
3. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
4. American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.
Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise
With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.
Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.
Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories
Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)
Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)
- ADME/Tox
- Molecular Biology
- The Art of Cell Culture
- Exosomes
- Stability Services
- Potency Assay
- Gene Therapy Assays
- Immunotherapy Assays
- Antiviral Therapy Assays
- cGMP
- MLR
- Cell Based Assays
- ELISA
- Flow Cytometry
- Protein
- PCR-qPCR
- Immunoassay
- Radioimmunoassay
- GLP
- Transfection
- Cell Therapy Assays
- Targeted Protein Degradation
- Research to Commercialization
